PWE-047 Improved patient-reported outcomes with upadacitinib over 52 weeks in patients with moderate-to-severe crohn’s disease
Laurent Peyrin‐Biroulet(Délégation Centre-Est), Subrata Ghosh(University College Cork), Fabio Cataldi(Pfizer (United States)), Édouard Louis(Centre Hospitalier Universitaire de Liège), Ana P. Lacerda(AbbVie (United States)), Edward V. Loftus(Mayo Clinic), Wen‐Jeng Lee(AbbVie (United States))
Cited by 0
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k